Gilead Sciences, Inc. (GILD)
- Previous Close
64.92 - Open
65.15 - Bid 64.55 x 600
- Ask 64.61 x 600
- Day's Range
64.52 - 65.22 - 52 Week Range
64.33 - 87.87 - Volume
6,021,471 - Avg. Volume
7,181,201 - Market Cap (intraday)
80.457B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
179.39 - EPS (TTM)
0.36 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield 3.08 (4.77%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
81.29
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
www.gilead.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GILD
Performance Overview: GILD
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GILD
Valuation Measures
Market Cap
80.48B
Enterprise Value
100.96B
Trailing P/E
179.44
Forward P/E
16.86
PEG Ratio (5yr expected)
0.80
Price/Sales (ttm)
2.95
Price/Book (mrq)
4.59
Enterprise Value/Revenue
3.68
Enterprise Value/EBITDA
21.10
Financial Highlights
Profitability and Income Statement
Profit Margin
1.77%
Return on Assets (ttm)
10.63%
Return on Equity (ttm)
2.39%
Revenue (ttm)
27.45B
Net Income Avi to Common (ttm)
485M
Diluted EPS (ttm)
0.36
Balance Sheet and Cash Flow
Total Cash (mrq)
4.72B
Total Debt/Equity (mrq)
147.93%
Levered Free Cash Flow (ttm)
12.51B
Research Analysis: GILD
Company Insights: GILD
GILD does not have Company Insights